Evidence map›Paper›PMID 37301731›Full record

ArticleThe Medical journal of Australia2023

The health care and societal costs of inherited retinal diseases in Australia: a microsimulation modelling study.

Deborah Schofield, Joshua Kraindler, Owen Tan, Rupendra N Shrestha, Sarah West, Natalie Hart, Liny Tan, Alan Ma, John R Grigg, Robyn V Jamieson

Open access · hybridAbstract read
In one paragraph

Article in The Medical journal of Australia, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
11.4field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it, 20 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Genetic engineering and the eye.Eye (London, England) · 2025
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 3 countries.

Deborah SchofieldGenIMPACT: Centre for Economic Impacts of Genomic Medicine, Macquarie Business School, Macquarie University, Sydney, NSW.
Joshua KraindlerGenIMPACT: Centre for Economic Impacts of Genomic Medicine, Macquarie Business School, Macquarie University, Sydney, NSW.ORCID 0000-0003-2103-6726
Owen TanGenIMPACT: Centre for Economic Impacts of Genomic Medicine, Macquarie Business School, Macquarie University, Sydney, NSW.
Rupendra N ShresthaGenIMPACT: Centre for Economic Impacts of Genomic Medicine, Macquarie Business School, Macquarie University, Sydney, NSW.ORCID 0000-0001-5455-0735
Sarah WestGenIMPACT: Centre for Economic Impacts of Genomic Medicine, Macquarie Business School, Macquarie University, Sydney, NSW.
Natalie HartGenIMPACT: Centre for Economic Impacts of Genomic Medicine, Macquarie Business School, Macquarie University, Sydney, NSW.
Liny TanChildren's Medical Research Institute, Sydney Children's Hospitals Network, University of Sydney, Sydney, NSW.
Alan MaChildren's Medical Research Institute, Sydney Children's Hospitals Network, University of Sydney, Sydney, NSW.ORCID 0000-0002-9293-4753
John R GriggChildren's Medical Research Institute, Sydney Children's Hospitals Network, University of Sydney, Sydney, NSW.
Robyn V JamiesonChildren's Medical Research Institute, Sydney Children's Hospitals Network, University of Sydney, Sydney, NSW.
Impact · CAThe University of Sydney · AU

Funding

Luminesce AllianceNational Health and Medical Research Council AAP1116360
6 · The paper itself

Abstract

objectivesTo estimate the health care and societal costs of inherited retinal diseases (IRDs) in Australia. DESIGN, SETTING,

participantsMicrosimulation modelling study based on primary data - collected in interviews of people with IRDs who had ophthalmic or genetic consultations at the Children's Hospital at Westmead or the Save Sight Institute (both Sydney) during 1 January 2019 - 31 December 2020, and of their carers and spouses - and linked Medicare Benefits Schedule (MBS) and Pharmaceutical Benefits Schedule (PBS) data.

main outcome measuresAnnual and lifetime costs for people with IRDs and for their carers and spouses, grouped by payer (Australian government, state governments, individuals, private health insurance) and type (health care costs; societal costs: social support, National Disability Insurance Scheme (NDIS), income and taxation, costs associated with caring for family members with IRDs); estimated annual national cost of IRDs.

resultsNinety-four people (74 adults, 20 people under 18 years; 55 girls and women [59%]) and 30 carers completed study surveys (participation rate: adults, 66%; children, 66%; carers, 63%). Total estimated lifetime cost was $5.2 million per person with an IRD, of which 87% were societal and 13% health care costs. The three highest cost items were lost income for people with IRDs ($1.4 million), lost income for their carers and spouses ($1.1 million), and social spending by the Australian government (excluding NDIS expenses: $1.0 million). Annual costs were twice as high for people who were legally blind as for those with less impaired vision ($83 910 v $41 357 per person). The estimated total annual cost of IRDs in Australia was $781 million to $1.56 billion.

conclusionAs the societal costs associated with IRDs are much larger than the health care costs, both contributors should be considered when assessing the cost-effectiveness of interventions for people with IRDs. The increasing loss of income across life reflects the impact of IRDs on employment and career opportunities.

Indexed as

National Health ProgramsRetinal DiseasesAdolescentAdultAgedAustraliaChildCost of IllnessEmploymentFemaleHealth Care CostsHumansCost of illnessOphthalmologyRetinal diseases

Identifiers

PMID37301731
PMCPMC10952471
OpenAlexW4380201313

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.